Dr. Reddy launches tablets to cure insomnia in US market

Dr. Reddy launches tablets to cure insomnia in US market

Nidhi Jani
/ Categories: Trending

Hyderabad-based pharma major Dr. Reddy's Laboratories has announced the launch of Ramelteon Tablets, 8 mg in the US market on Tuesday.

Ramelteon Tablets are used to treat insomnia that is associated with having trouble falling asleep. As per IQVIA health data, the medication has a projected market size of US$91.3 million in the 12-month period ending May 2019 in the US markets.

Looking at the last quarter Q4FY19, the company's revenue increased by 14 per cent on YoY basis and PAT jumped by 10.8 per cent on YoY basis. The company’s Q4FY19 sales mix comprises of North America (37 per cent), Europe (5 per cent), India (16 per cent), Emerging markets (17 per cent), PSAI (17 per cent) and Proprietary Products & Others (8 per cent).

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

On Tuesday, the stock of Dr.Reddy's Laboratories opened at Rs. 2,632 per share and made an intraday high and low of Rs. 2,640.55 and Rs. 2,581.30, respectively on the BSE. Finally, the stock settled at Rs. 2,600, down by 31.95 points or 1.21 per cent.

Previous Article Quarterly Results to watch out on July 24
Next Article Technical Bits: MCX forms Bearish engulfing candle
Rate this article:
5.0

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR